Refractory reflux syndromes associated with ... 7,8 In young patients, symptoms are acute and often associated with odynophagia, chest pain and dysphagia, as well as heartburn.

and in the long-term treatment of refractory disease with persistent chronic pain. For acute pain, we use short-acting opioid preparations containing oxycodone or hydrocodone. For persistent pain ...

The Food and Drug Administration (FDA) has approved Aucatzyl ® (obecabtagene autoleucel; obe-cel) for the treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL) in ...

A recent randomized controlled trial has shed light on the efficacy of acupuncture as a treatment for refractory irritable ...

A randomized controlled trial has shed light on the efficacy of acupuncture as a treatment for refractory irritable bowel ...

Injected micronized amnion/chorion bilayer (AC) product significantly reduces time to symptom relief in patients with ...

Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the ...

The CAR-T cell therapy Aucatzyl was approved for relapsed or refractory B-cell precursor acute lymphoblastic leukemia based ...

The toxin strychnine, the primary component of the traditional Chinese medicine, may act in the STAT3 pathway, investigators ...

The FDA has approved obecabtagene autoleucel (Aucatzyl) to treat adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.

The FDA approved obecabtagene autoleucel (obe-cel; Aucatzyl) for treating relapsed or refractory B-cell precursor acute ...

Nevro (NVRO) announced the publication of new data in the Journal of Pain Research demonstrating significant, durable pain relief and long-term ...